INHIBIN A AS A PREDICTOR OF RECURRENT PREGNANCY LOSS IN WOMEN WITH HYPERPROLACTINEMIA
Abstract
Background. Recurrent pregnancy loss (RPL) remains a significant challenge in obstetric practice, impacting the physical and psychological well-being of affected women. Hyperprolactinemia, a common endocrine disorder among women of reproductive age, is associated with an increased risk of early pregnancy loss. Research Objective. To evaluate inhibin A as a biomarker for predicting recurrent pregnancy loss in women suffering from hyperprolactinemia and to highlight its diagnostic significance in early gestation. The article presents a comprehensive review of clinical and experimental findings related to inhibin A secretion dynamics, its role in endocrine regulation, and its diagnostic relevance in early pregnancy complications. The relationship between hyperprolactinemia and impairments in endometrial receptivity, luteal phase function, and hormonal support of early pregnancy is discussed in detail. Additionally, comparative analyses of inhibin A levels in normal versus complicated pregnancies are examined, with attention to its fluctuations across gestational trimesters.
About the Authors
List of references
Abdulkadyrova ZK, Abashova EI. Inhibin as a reproductive biomarker. Part 1. Journal of Obstetrics and Women’s Diseases. 2019;68(3):61-70. https://doi.org/10.17816/JOWD68361-70
Abdulkadyrova ZK, Yarmolinskaya MI, Gzgzyan AM, et al. Inhibin as a reproductive biomarker. Part 2. Clinical significance of inhibins in reproductive medicine. Journal of Obstetrics and Women’s Diseases. 2019;68(5):91-106. https://doi.org/10.17816/JOWD68591-106
Chester M.R., Tirlapur A. and Jayaprakasan K. (2022), Current management of recurrent pregnancy loss. Obstet Gynecol,24: 260-271. https://doi.org/10.1111/tog.12832
Ciarmela P, Florio P, Toti P, et al. Expression of betaglycan in pregnant issues throughout gestation. Eur J Endocrinol. 2003:433-437 https://doi.org/10.1530/eje.0.1490433.
Erol O, Süren D, Tutuş B, et al. Immunohistochemical analysis of E-cadherin, p53 and inhibin-α expression in hydatidiform mole and hydropic abortion. Pathol Oncol Res. 2016;22(3):515-521. https://doi.org/10.1007/s12253-015-0031-8.
European Society of Human Reproduction and Embryology (ESHRE). Recurrent pregnancy loss. Strombeek-Bever: ESHRE; 2017 https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspx Google Scholar
Endocrine Abnormalities in RPL| Obgyn key. Дата обращения:15.01.2025 https://obgynkey.com/endocrine-abnormalities-in-rpl/
Олина А.А. Неразвивающаяся беременность и гиперпролактинемия. РМЖ. Мать и дитя.2020; (2):64-69. DOI:10.32364/2618-8430-2020-3-64-69 https://www.rmj.ru/articles/akusherstvo/Nerazvivayuschayasya_beremennosty_i_giperprolaktinemiya_Esty_li_mesto_rastitelynym_preparatam_v_terapii/#ixzz8ZozpfcCW
Jones RL, Salamonsen LA, Critchley HO, et al. Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception. Mol Hum Reprod. 2000;6(12):1107-1117. https://doi.org/10.1093/molehr/6.12.1107
Muttukrishna S, George L, Fowler PA, et al. Measurement of serum concentrations of inhibin-A (α-β A dimer) during human pregnancy. Clin Endocrinol (Oxf). 1995;42(4):391-397. https://doi.org/10.1111/j.1365-2265.1995.tb02648.x.
Namwanje M, Brown CW. Activins and Inhibins: Roles in Development, Physiology, and Disease. Cold Spring Harb Perspect Biol. 2016;8(7):a021881. https://doi.org/10.1101/cshperspect.a02188
Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 2012; 98: 1103–11.
Royal College of Obstetricians and Gynaecologists (RCOG). The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage. Green-top guideline No. 17. London: RCOG; 2011
Sosnova E.A. Hyperprolactinemic syndrome. V.F. Snegirev Archives of Obstetrics and Gynecology, Russian journal. 2017; 4(1): 4—14. (In Russ.). DOI: http://dx.doi.org/10.18821/23138726201741414
Stenvers KL, Findlay JK. Inhibins and activins: towards the future. A tribute to the late Professor Wylie W. Vale. Mol Cell Endocrinol. 2012;359(1-2):1. https://doi.org/10.1016/j.mce.2012.03.001
Treetampinich C, O‘Connor AE, MacLachlan V, et al. Maternal serum inhibin A concentrations in early pregnancy after IVF and embryo transfer reflect the corpus luteum contribution and pregnancy outcome. Hum Reprod. 2000;15(9):2028-2032. https://doi.org/10.1093/humrep/15.9.2028.
Turasheva A., Aimagambetova G., Ukybassova T., and et al. 2023. «Recurrent pregnancy loss etiology, risk factors, diagnosis, and management. Fresh look into a full box» Journal of clinical medicine 12, no.12:4074 https://doi.org/10.3390/jcm12124074
Wijayarathna R, de Kretser DM. Activins in reproductive biology and beyond. Hum Reprod Update. 2016;22(3):342- 357. https://doi.org/10.1093/humupd/dmv058.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.